Key result
Novel plasminogen activators engineered from human tissue plasminogen activator or animal and bacterial proteins may provide faster reperfusion with less bleeding risk.
Why the study?
Do novel plasminogen activators improve reperfusion and reduce bleeding risk in patients with myocardial infarction?
Do novel plasminogen activators improve reperfusion and reduce bleeding risk in patients with myocardial infarction?
This review highlights the pharmacologic profiles and clinical potential of novel plasminogen activators to achieve faster reperfusion with improved safety in myocardial infarction.
Suggests a promising safety and efficacy profile for next-generation thrombolytics in myocardial infarction; leaves.
Rapid restoration of patency of the infarct-related artery is the key to preserving myocardium and improving survival. This understanding has led to the application of genetic engineering to develop new plasminogen activators with specific clinical features. These novel activators may provide faster and more complete reperfusion in a greater number of patients, and do so with less risk of bleeding and intracranial hemorrhage. This article reviews the pharmacologic profiles and clinical performance of several novel plasminogen activators engineered from the human tissue plasminogen activator molecule or developed from animal and bacterial proteins.
No takes yet. Share an insight, caveat, or question.
Allan M. Ross (1999) conducted a review in Myocardial infarction. Novel plasminogen activators was evaluated. Novel plasminogen activators engineered from human tissue plasminogen activator or animal and bacterial proteins may provide faster reperfusion with less bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: